Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Apixaban 2 5 mg price?

See the DrugPatentWatch profile for Apixaban

Prices vary a lot by country, pharmacy, strength, and whether you’re buying brand-name or generic. If you’re asking about the U.S. market and the common 5 mg strength taken as two tablets per day (60 tablets = about a 30‑day supply):

- Brand-name Eliquis (apixaban) 5 mg, 60 tablets: roughly $600–$700 out of pocket without insurance.
- Generic apixaban 5 mg, 60 tablets: roughly $300–$450 with coupons or insurance discounts.

If you’re in another country or you need a different quantity/strength (for example 2.5 mg tablets), prices can be quite different.

If you’d like, tell me:
- your country/location
- whether you want brand-name or generic
- the exact strength and how many tablets you need (quantity)
I can give you a more tailored ballpark price and show you how to check current prices at local pharmacies.



Other Questions About Apixaban :

Patentlaufzeit apixaban deutschland? Apixaban brand name philippines? Apixaban eliquis average total drug cost per prescription 2023? Wann lauft apixaban patent ab? When does apixaban's patent expire exactly? Generic apixaban availability 2025 united states? Apixaban nombre comercial y generico?

AI-Drug Label Prescribing Information Alignment Report

100
100%
Grade A

Excellent

Aligned

Patient Risk: Low

Summary

The AI claim accurately reflects the FDA label text in Warnings and Precautions sections 5.1 and 5.3, including the stated thrombotic/stroke risk with premature discontinuation and the neuraxial/spinal puncture-related risk of epidural/spinal hematoma potentially causing long-term or permanent paralysis.


Category Scores

Warnings
100
Excellent

Accurate Statements

The label warns that discontinuing ELIQUIS prematurely increases the risk of thrombotic events (including stroke).
Supported by SECTION 5.1 (Increased Risk of Thrombotic Events after Premature Discontinuation).
The label warns that neuraxial anesthesia/spinal puncture can cause epidural/spinal hematoma potentially leading to long-term or permanent paralysis.
Supported by SECTION 5.3 (Spinal/Epidural Anesthesia or Puncture).

Unsupported Statements


Contradictions


Important Omissions


Safety Assessment

Potential Patient Risk: Low
The evaluated statements are directly supported by the label warnings and do not introduce unsubstantiated or contradictory safety claims.

Regulatory Assessment

On Label Yes
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Low

Recommendation

Aligned

Primary Issue

Suggested Improvement